Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Investorview – Zishan Haroon, Chairman & General P...

In a new regular feature for Drugs & Dealers, we’ll be interviewing some of...

Read More

The role of SFOs in the Healthcare Sector

Our ongoing mission at Biotech and Money is to forge a fundamentally better...

Read More

7 questions with Isobel Finnie, Europe and UK pate...

Biotech and Money recently caught up with Europe and UK patent attorney Iso...

Read More

Investment Philosophies and Fundamental Trends

Biotech and Money had the opportunity to speak to Andy Smith CIO of Mann Bi...

Read More

Interview with Andy Richards, Serial Biotechnology...

We recently spoke to Andy Richards, Serial Biotechnology Entrepreneur and B...

Read More

Exclusive Interview with Peter George, CEO, Clinig...

We recently spoke toPeter George, CEO, Clinigen at Biotech and Money London...

Read More

Biotech and Money London 2016 Post Event Report

On the 2nd and 3rd February, Biotech and Money London welcome over 360 of t...

Read More

Biotech and Money London 2016 report: UK biotech b...

Ever since the collapse of British Biotech more than a decade ago, the UK l...

Read More

[REPORT] The State of the UK's Healthcare Life Sci...

The UK’s leading life science and healthcare company CEO’s, leading investo...

Read More

[ONES TO WATCH] Life Science showcases announced a...

At the 2nd annual Biotech and Money London conference, we’re all about givi...

Read More

ISSUE 8, 2016 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

[EBOOK] Get the Brand New Investor Interview with ...

Biotech and Money recently caught up with Mark Denham, Fund Manager and Hea...

Read More
  • Prev

Add Your Response